On August 25, Hengrui Medicine (600276/01276) issued an announcement that the company recently received the "Drug Clinical Trial Approval Notice" for HRS-6093 tablets approved and issued by the National Medical Products Administration, and will conduct clinical trials in the near future.

This drug is a novel, highly potent, and selective oral KRASG12D inhibitor that specifically binds to the mutant KRASG12D protein, exerting anti-tumor effects. Currently, no similar products have been approved for marketing in China or abroad. To date, the cumulative R&D investment in the HRS-6093 tablet project has reached approximately 29.84 million yuan.

According to the relevant laws and regulations on drug registration, after obtaining approval for clinical trials, drugs still need to undergo clinical trials and be reviewed and approved by the National Medical Products Administration before they can be produced and marketed. There is uncertainty in the drug research and development and marketing process.

By mid-2025, Hengrui Medicine achieved revenue of 15.761 billion yuan and net profit attributable to shareholders of the parent company of 4.450 billion yuan.

https://finance.eastmoney.com/a/202508253493609477.html